hot slots game

LeBron James is going to have to make room for the NFL. Wednesday's doubleheader on Netflix set records as the most-streamed NFL games in U.S. history, with numbers nearly five times more than the NBA. The Baltimore Ravens' 31-2 victory over the Houston Texans averaged 24.3 million while Kansas City's 29-10 win at Pittsburgh averaged 24.1 according to early viewer figures released by Nielsen on Thursday. Nielsen also said there were 65 million U.S. viewers who tuned in for at least one minute of one of the two games. The NBA's five-game slate averaged about 5.25 million viewers per game across ABC, ESPN and its platforms, according to the league and Nielsen. “I love the NFL,” James said in his televised postgame interview Wednesday night. “But Christmas is our day.” While the NBA's Christmas lineup has its best viewer numbers in five years, the NFL has made Christmas one of its tentpole events during the regular season, joining Kickoff Weekend and Thanksgiving. “The numbers speak for themselves and LeBron can have his own view, and I’m sure more people will look at that because of this," said Hans Schroeder, the executive vice president of NFL Media. "But, you know, we’re focused on the NFL and we’re thrilled with the results this year with the Christmas on Netflix and we’re excited to continue to build that over the next couple of years.” Both NFL games surpassed the previous mark of 23 million for last season’s AFC wild-card game between the Miami Dolphins and Chiefs on Peacock. Viewership for Ravens-Texans peaked with the Beyoncé Bowl. The 20-minute halftime performance averaged over 27 million viewers. The viewer figures include the audience on Netflix, mobile viewership on NFL+ and those who tuned in on CBS stations in Pittsburgh, Kansas City, Baltimore and Houston. Global ratings and final U.S. numbers are expected to be available on Tuesday. The NFL's Christmas numbers decreased from last season, but not at the rate that usually happens when something goes from broadcast to streaming. Last year’s three games averaged 28.68 million viewers. The early afternoon contest between the Las Vegas Raiders and Chiefs led the way, averaging 29.48 million on CBS. Once global and Netflix's first-party data is released, both Christmas games should surpass 30 million. The NBA's lineup saw an 84% rise over 2023. One reason for the increase is that all five games were on ABC, compared to two last year. The Los Angeles Lakers’ 115-113 victory over the Golden State Warriors — a game pitting Olympic teammates LeBron James and Stephen Curry — averaged 7.76 million viewers and peaked with about 8.32 million viewers toward the end of the contest, the league said. Those numbers represent the most-watched NBA regular season game in five years. The NBA said all five Christmas games on its schedule — San Antonio at New York in Victor Wembanyama's holiday debut, Minnesota at Dallas, Philadelphia at Boston, Denver at Phoenix and Lakers-Warriors — saw year-over-year viewership increases. Wednesday's numbers pushed NBA viewership for the season across ESPN platforms to up 4% over last season. The league also saw more than 500 million video views on its social media platforms Wednesday, a new record. For the NBA, those are all good signs amid cries that NBA viewership is hurting. “Ratings are down a bit at beginning of the season. But cable television viewership is down double digits so far this year versus last year," NBA Commissioner Adam Silver said earlier this month. “You know, we’re almost at the inflection point where people are watching more programing on streaming than they are on traditional television. And it’s a reason why for our new television deals, which we enter into next year, every game is going to be available on a streaming service.” Part of that new package of television deals that the NBA is entering into next season also increases the number of regular season games broadcast on television from 15 to 75. AP NBA: https://www.apnews.com/hub/NBAOTTAWA — The House of Commons Speaker has intervened to end a parliamentary impasse, ruling that members of Parliament must debate and vote on opposition motions and government spending before returning to a Conservative filibuster that has dragged on for two months. Speaker Greg Fergus made the ruling Monday afternoon as a deadline for those motions and spending votes to happen just one week away. "This is a situation that Parliament has never been in before," Liberal House leader Karina Gould told reporters on Monday. Last week, the Conservatives signalled an intent to introduce a non-confidence motion quoting NDP Leader Jagmeet Singh's criticism of the Liberals, in a bid to get his caucus to vote to bring down the minority government. That would be the third non-confidence motion the Conservatives have introduced this fall sitting. No opposition days have been held since early October because the House has been bogged down in debate over a matter of privilege, which has consumed most of the sitting time for nearly two months and is jeopardizing the government's ability to get spending approved. The filibuster stems from a Conservative demand that the Liberals provide unredacted documents to the RCMP about allegations of misspending at a now-defunct green technology fund. Monday morning, Gould offered to hold opposition days this week if members of Parliament unanimously agreed to temporarily suspend the filibuster, but the Tories rejected that. Gould characterized the Conservatives' tactics as "disappointing or pathetic," saying all other parties had agreed to move forward. "They’re talking of a big game and all this stuff, and when the rubber hits the road they’re actually too afraid to move forward," she told reporters on Parliament Hill. Eventually, Fergus told the Commons he had scheduled opposition days for Thursday and Friday, meaning the government could face another non-confidence vote as early as Monday. Gould's office later said the first motion to be heard Thursday will come from the Conservatives, and is set for a vote Monday after question period. The second motion, set to be heard Friday, will come from the NDP and would receive a vote around the same time. Another two Conservative motions would be heard Monday and Tuesday, with both set for a vote on Tuesday, barring changes to those plans. Voting on departmental spending would likely follow. Fergus said his ruling was a way to balance the opposition's right to have its motions debated and Parliament's prerogative to scrutinize government spending. He said he had asked the parties to find a solution to the gridlock, for which "the discussions do not seem to have been productive." Opposition parties must be given four days to introduce their own motions before Dec. 10. That is also the deadline for the House to vote to approve billions of dollars in spending, without which some government departments risk running out of money. Treasury Board President Anita Anand introduced a request last month for $21.6 billion to fund programs including housing, dental care and the national school food program. Conservative House leader Andrew Scheer wrote in a statement that Gould's proposal amounted to a coverup of the misspending allegations. "The Liberals tried a sneaky procedural trick today to suspend questions into their scandal," he said in a statement. "Even the Liberal Speaker has ruled that Justin Trudeau must face opposition debate on nine years of his failures," he wrote, confirming the Conservatives will put forward three non-confidence motions. The Tories say they will only end their filibuster if the Liberals provide documents they're demanding, or if the NDP agrees to vote non-confidence in the government. Two Conservative opposition motions declaring non-confidence in the government were defeated in September with the Bloc Québécois and the NDP voting against them. The Bloc has since pledged to work with the other opposition parties to defeat the government after the Liberals refused to adopt a Bloc bill to raise old age security payments for seniors under age 75. However, Bloc Leader Yves-François Blanchet said his party would only vote in favour of non-confidence motions that are deemed to be in the best interests of Quebec. Singh has said his party will take each non-confidence vote on a case-by-case basis, and has said that while his party is ready for an election it does not want to push for one immediately. This report by The Canadian Press was first published Dec. 2, 2024. Dylan Robertson, The Canadian Press

Credit: HCPLive Ophthalmology achieved groundbreaking advancements in 2024, with innovative therapies and cutting-edge technologies reshaping care for some of the most challenging eye conditions. From the US Food and Drug Administration (FDA) approval of the first home optical coherence tomography (OCT) device to advances in gene therapy for neovascular age-related macular degeneration (nAMD) and retinitis pigmentosa, the year brought significant milestones in patient care. Regulatory breakthroughs, including the authorization of autonomous artificial intelligence (AI) for portable diabetic retinopathy screening and the approval of novel therapies like clobetasol propionate eye drops for post-surgical pain, demonstrated a commitment to improving accessibility and outcomes. On the innovation front, new treatment modalities continued to make huge strides. Promising data from trials of RGX-314 and Ixo-vec reinforced the potential of long-term solutions for reducing treatment burden in nAMD, while groundbreaking results for oral gildeuretinol offered hope for slowing geographic atrophy progression. Regulatory shifts, such as the reintroduction of Susvimo and the approval of a prefilled syringe for faricimab, further simplified treatment delivery for retinal diseases. As the year draws to a end, these advancements highlight an exciting future for ophthalmology, with patient-centric approaches driving progress in vision preservation and restoration. On January 16, 2024, Tarsier Pharma received agreement from the FDA under a Special Protocol Assessment (SPA) for the Phase 3 Tarsier-04 trial investigating TRS01 eye drops (Dazdotuftide) for the treatment of non-infectious uveitis, including uveitic glaucoma. The regulatory agency agreed the clinical trial protocol and planned statistical analysis of Phase 3 trial would address objectives supporting regulatory submission. On March 4, 2024, the FDA approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) for treating post-operative inflammation and pain following ocular surgery. Awarded to a collaborative team of Formosa Pharmaceuticals and AimMax Therapeutics, clobetasol propionate ophthalmic suspension 0.05% for post-ocular surgery pain marks the first new steroid in the ophthalmic market in over 15 years. Subretinal delivery of ABBV-RGX-314, a potential one-time gene therapy, was well-tolerated without a clinically recognized immune response in the treatment of neovascular (wet) age-related macular degeneration (nAMD) in phase 1/2a trial results. These 2-year data suggested the novel approach of RGX-314 for sustained vascular endothelial growth factor (VEGF)-A suppression could safely maintain vision and reduce treatment burden after a single dose. On April 30, 2024, the FDA cleared the first, fully autonomous artificial intelligence (AI) for portable diabetic retinopathy screening, with the ability to diagnose the disease from retinal images obtained by a handheld camera. Awarded to AEYE Health, the AEYE Diagnostic Screening (AEYE-DS) technology marked the first autonomous AI solution to allow accessible, portable screening using the Optomed Aurora device. Topline results from the Phase 2 PAVIA trial found the vorolanib intravitreal insert (DURAVYUTM) missed its pre-specified primary endpoint, without displaying an improvement of ≥2 Diabetic Retinopathy Severity Scale (DRSS) by week 36. Announced by Eyepoint Pharmaceuticals, the company still reported Duravyu stabilized or improved disease severity with reduced rates of NPDR progression and a favorable safety and tolerability profile. On July 4, 2024, the FDA approved a 6.0 mg single-dose prefilled syringe of faricimab (Vabysmo) for use in the treatment of a trio of ophthalmic disorders, including nAMD, diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Awarded to Genentech, the prefilled syringe is designed to simplify administration and marked the first and only syringe with an FDA-approved bispecific antibody to treat retinal conditions. FDA Accepts sBLA for Susvimo in Treatment of DME, Diabetic Retinopathy On July 8, 2024, Genentech/Roche has signaled the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via an ocular implant for neovascular (wet) age-related macular degeneration (nAMD), marking the end of a voluntary recall. The FDA granted a post-approval supplement to the Biologics License Application for Susvimo based on component-level updates to the ocular implant and refill needle. Later that month, on July 18, 2024, the FDA accepted the supplemental BLA (sBLA) for Susvimo for the treatment of DME and diabetic retinopathy. The filing was accepted based on the 1-year study results from the Phase 3 Pagoda and Pavilion studies, with both studies meeting their primary endpoints of non-inferior visual acuity gains from baseline to monthly ranibizumab and superior improvements on the Diabetic Retinopathy Severity Scale (DRSS) to clinical observation, respectively. On September 17, 2024, Alkeus Pharmaceuticals announced oral gildeuretinol acetate (ALK-001) achieved a clinically meaningful reduction in geographic atrophy (GA) lesion growth at 24 months in patients with GA secondary to AMD. Gildeuretinol, a novel molecule created as a specialized form of deuterated Vitamin A, also achieved a statistically significant slowing of low-luminance visual acuity (LLVA) decline at 24 months, with a favorable safety and tolerability profile in patients with GA. On October 9, 2024, Clearside Biomedical announced axitinib injectable suspension (CLS-AX) achieved all primary and secondary outcomes in the treatment of nAMD in the Phase 2b ODYSSEY trial. Suprachoroidal CLS-AX demonstrated stability in visual acuity and anatomical control for up to 6 months, with a well-tolerated safety profile without ocular or treatment-related serious adverse events (SAEs). On October 3, 2024, Aldeyra Therapeutics resubmitted a New Drug Application (NDA) to the FDA for their investigational new drug candidate, topical ocular reproxalap, for the treatment of signs and symptoms of dry eye disease (DED). The resubmitted NDA for reproxalap included positive results from a recently finished Phase 3 DED symptom trial requested by the FDA after a Complete Response Letter (CRL) received in Novemebr 2023. The resubmitted NDA also involved a draft label reflecting acute activity in reducing dry eye symptoms in a dry eye chamber trial, chronic activity in reducing dry eye symptoms in a field trial, and acute activity in reducing ocular redness in two dry eye chamber trials. RESTORE: MCO-010 Achieves Significant Vision Restoration in Retinitis Pigmentosa On October 10, 2024, Nanoscope Therapeutics announced plans to submit the Biologics License Application (BLA) for MCO-010 gene therapy for the treatment of severe vision loss due to retinitis pigmentosa in the first quarter of 2025. The announcement followed a productive meeting with the FDA discussing the MCO-010 clinical trial program with the agency acknowledging the company’s proposal for the next steps for submission. Earlier in the year, positive topline results from the 2-year Phase 2b RESTORE trial showed statistically significant and clinically meaningful improvement in best-corrected visual acuity (BCVA) with MCO-010 in patients with permanent and severe vision loss from advanced retinitis pigmentosa. On November 15, 2024, the FDA issued a CRL for the supplemental New Drug Application (sNDA) of avacincaptad pegol intravitreal solution (IZERVAY) for the treatment of GA secondary to AMD. Announced by Astellas Pharma, the sNDA was intended to include new positive Phase 3 2-year data from the GATHER2 trial in the US prescribing information. Intended for a decision by its Prescription Drug User Fee Act (PDUFA) target action date of November 19, 2024, the FDA indicated it cannot approve the sNDA in its present form, owing to comments on a statistical matter related to labeling language proposed by Astellas. The agency outlined no comments on the safety or benefit-risk profile of avacincaptad pegol for GA secondary to AMD. On November 18, 2024, Alkeus Pharmaceuticals announced gildeuretinol (ALK-001), an investigational oral therapy, received Rare Pediatric Disease and Fast Track designations from the FDA for the treatment of Stargardt disease. The company indicated its plans to apply for a Priority Review voucher with the submission of the NDA for gildeuretinol for Stargardt. On November 18, 2024, Adverum Biotechnologies announced topline 1-year results from the LUNA Phase 2 trial and 4-year follow-up of the OPTIC first-in-human trial. These data supported the long-term potential of intravitreal ixoberogene soroparvovec (Ixo-vec) gene therapy for patients with nAMD, with 52-week efficacy data on the 6E10 dose and 4-year data on the 2E11 dose demonstrating maintenance of visual and anatomic endpoints, with an ≥80% reduction in injection burden and ≥50% injection freedom. Traditional optical coherence tomography (OCT) devices require a patient with retinal diseases to visit an office, an often time-consuming task, and there is a delay between scans which can lead to disease progression. In May 2024, the FDA granted De Novo authorization to Notal Vision’s patient self-operated home OCT product, Scanly, for the monitoring of retinal diseases at home, including nAMD. In our This Year in Medicine feature, we take a look at how the device could provide eye care professionals unprecedented insight into how treatments work in real-time, empowering patients to take a more active role in preserving their vision.Falcons visit Vikings as a struggling Cousins returns to old home to find a thriving Darnold

Falcons visit Vikings as a struggling Cousins returns to old home to find a thriving Darnold

OpenAI whistleblower death: Parents want to know what happened to Suchir Balaji after apparent suicide

Published 4:47 pm Friday, November 22, 2024 By Data Skrive At 3 p.m. ET on Saturday, the Alcorn State Braves (6-5) take on Irvin Mulligan and the Jackson State Tigers (9-2). We provide more details below, including how to watch this game on ESPN+. Watch college football live without cable. Stream ACC, SEC, ESPN and more with Fubo. What is Fubo? Fubo is a streaming service that gives you access to your favorite live sports and shows on demand. Start your risk free trial today and start watching college football games now. Stop missing games and start streaming college football right now on Fubo. Stop missing games and start streaming college football right now on ESPN+. Get tickets for any college football game this season at Ticketmaster. Rep your favorite players with officially licensed gear. Head to Fanatics to find jerseys, shirts, hats, and much more.

DETROIT (AP) — Starting in September of 2027, all new passenger vehicles in the U.S. will have to sound a warning if rear-seat passengers don’t buckle up. Related Articles National News | Former TV host Carlos Watson gets nearly 10 years in prison in case about failed startup Ozy Media National News | TikTok asks the Supreme Court for an emergency order to block a US ban unless it’s sold National News | Survivors seek a reckoning as FBI investigates child sex abuse in little-known Christian sect National News | Trump migrant deportations could threaten states’ agricultural economies National News | Federal Reserve is likely to slow its rate cuts with inflation pressures still elevated The National Highway Traffic Safety Administration said Monday that it finalized the rule, which also requires enhanced warnings when front seat belts aren’t fastened. The agency estimates that the new rule will save 50 lives per year and prevent 500 injuries when fully in effect, according to a statement. The new rule will apply to passenger cars, trucks, buses except for school buses, and multipurpose vehicles weighing up to 10,000 pounds. Before the rule, seat belt warnings were required only for the driver’s seat. Under the new rule, outboard front-seat passengers also must get a warning if they don’t fasten their belts. Front-center seats will not get a warning because NHTSA found that it wouldn’t be cost effective. The agency said most vehicles already have warnings for the outboard passenger seats. The rule also lengthens the duration of audio and visual warnings for the driver’s seat. The front-seat rules are effective starting Sept. 1 of 2026. Rear passengers consistently use seat belts at a lower rate than front passengers, the agency says. In 2022, front belt use was just under 92%, while rear use dropped to about 82%. About half of automobile passengers who died in crashes two years ago weren’t wearing belts, according to NHTSA data. The seat belt rule is the second significant regulation to come from NHTSA in the past two months. In November the agency bolstered its five-star auto safety ratings to include driver assistance technologies and pedestrian protection. Safety advocates want the Department of Transportation, which includes NHTSA, to finish several more rules before the end of the Biden administration, because President-elect Donald Trump has said he’s against new government regulations. Cathy Chase, president of Advocates for Highway and Auto Safety, urged the department to approve automatic emergency braking for heavy trucks and technology to prevent impaired driving.Ireland's Political Crossroads: Coalition Talks Intensify Post-ElectionEzra Mam will have to pay $120,000 in fines to Brisbane and the NRL, after the under-fire five-eighth accepted his nine-game ban for driving offences. The Broncos confirmed late on Friday evening that Mam would accept his NRL sanctions, which included a $30,000 fine. Brisbane have slapped the 22-year-old with an additional $90,000 fine for being caught drug driving while unlicensed after crashing his ute into an oncoming car in October. In a statement, the Broncos said Mam would also have to complete a safe-driving program, work or study placement and commit to ongoing wellbeing support. Mam was also fined $850 and had his license suspended for nine months in court last week , with a magistrate telling Mam he had a “cocktail of cocaine and other matters” in his system, and that he “could’ve injured or killed” someone. That punishment was widely been criticised as too lenient, after a woman and her young daughter were injured in the collision. Ezra Mam leaves Brisbane Magistrates Court after a hearing earlier this month. Credit: William Davis “Whilst we are extremely disappointed that we have been placed in this position, we believe both the NRL and club-imposed penalties adequately reflect the gravity of what’s transpired and should act as a deterrent from this type of risky and anti-social behaviour,” Broncos CEO Dave Donaghy said in a statement. “Ezra clearly did the wrong thing, but he has taken responsibility for his actions and shown genuine remorse towards those involved. “He understands the impact this has had on everyone around him, and the game. Ezra has taken steps to get his life back on track since this incident and that must continue. We have been very clear about that. “We believe the additional measures in place are important and will go hand in hand with integrating Ezra back into the work underway at the Broncos.” Mam will not be able to include the Indigenous All-Stars fixture to his ban, meaning he will not be able to return until Brisbane play South Sydney in round 10 of 2025. Ben Hunt is set to partner Adam Reynolds in the Broncos’ halves for the first two months of the season after his move from St George Illawarra. It is then possible Hunt could shift to hooker if Mam and Reynolds are fit, allowing him to share dummy-half duties with Billy Walters under new coach Michael Maguire. Hunt will also need to bring significant leadership to Brisbane, with Broncos bosses admitting it is lacking. Mam was one of their best players in 2023 as they went within a few minutes of ending a 17-year premiership drought, scoring a hat-trick in the grand-final loss to Penrith. But off-field issues returned to Red Hill in 2024, with co-captains Pat Carrigan and Reynolds involved in a scuffle outside of a bar following a pre-season fan day. Mam and Reece Walsh were then investigated by the NRL’s integrity unit over a post-season interaction with a fan, weeks before Mam’s driving offence. AAP